'It's A Runaway Train': Rick Allen Decries Government Spending In Healthcare

  • 3 months ago
During a House Education Committee hearing prior to the recess, Rep. Rick Allen (R-GA) spoke about federal spending in healthcare.

Fuel your success with Forbes. Gain unlimited access to premium journalism, including breaking news, groundbreaking in-depth reported stories, daily digests and more. Plus, members get a front-row seat at members-only events with leading thinkers and doers, access to premium video that can help you get ahead, an ad-light experience, early access to select products including NFT drops and more:

https://account.forbes.com/membership/?utm_source=youtube&utm_medium=display&utm_campaign=growth_non-sub_paid_subscribe_ytdescript


Stay Connected
Forbes on Facebook: http://fb.com/forbes
Forbes Video on Twitter: http://www.twitter.com/forbes
Forbes Video on Instagram: http://instagram.com/forbes
More From Forbes: http://forbes.com
Transcript
00:00Chairman, and thank you, Mr. Secretary, for being with us today. Now that the federal
00:05government owns and is running health care, we are encountering disastrous problems throughout
00:11the country. We are losing providers because of the oppressive policies of HHS and CMS.
00:18Patients are compromised by complicated rules requiring prior approvals and limits on care
00:25and rehabilitation. It is not free market and it is not free patients. It is all governed by this
00:33branch of the government. We are spending $4 trillion in this country on health care,
00:39$1.6 trillion in taxpayer dollars on health care in this country.
00:45When Medicare became law, three people were paying for each one Medicare recipient. Today,
00:52one American is paying for every three Medicare recipients.
00:58We have had some difficult policy made in the last 80 years in health care,
01:08and it is a runaway train. I have asked you this question every time you have come to this,
01:15and I served on the Healthy Future Task Force, and I couldn't get an answer there either.
01:23But I keep asking, where are all the dollars going? Who is getting them? Is it the federal
01:30agencies? The providers, their incomes are decreasing, as I understand it. Practices,
01:38hospitals are consolidating because of this problem, creating a problem everywhere.
01:43I have asked you that question. Have you all figured it out over there?
01:46Can you give me a breakdown of where every federal and paid dollar goes for health care?
01:55Well, here is the interesting thing, Congressman. I can tell you where the federal dollars go
01:59because we keep an accounting of it. I can't tell you where the private sector dollar goes.
02:03You mentioned prior authorization. That has nothing to do with the federal government.
02:06Prior authorization is something that the insurance companies came up with to try to
02:11keep providers from being able to offer the services that they believe are necessary.
02:16We can't get in that space because that's done by a private entity, that private business.
02:21I would tell you that the answer to your question, where are those dollars going,
02:25it's the middlemen. We've heard about all the money that's going into the PBMs.
02:30The PBMs are the ones that are essentially the go-betweens between pharmaceutical companies
02:36and the pharmacies and the dispensing. In between the pharmaceutical companies
02:41and the pharmacies, a whole bunch of money is in that system.
02:44I've got limited time here, but realize the insurance companies are basically in bed with
02:53the federal government. The federal government is running health care in this country.
02:57I never see them next to my pillow, I'll tell you that.
03:01Democrats passed a partisan bloated inflation reduction act, and the drug price setting
03:05provisions in this bill make developing treatments even more difficult by not
03:09allowing the cost of the development to be recouped, especially for small molecule products.
03:17Due to these differing timelines, there's concern in the medical community that the
03:20law does not provide enough time for small molecule manufacturers to recoup research
03:25and development costs. Could you tell me, yes or no, will HHS address the differing
03:30timelines between small and large molecule drugs to ensure it does not increase the cost
03:35of drugs for patients and does not disincentivize the innovation of drugs in the future?
03:42If you're speaking about the negotiation program that we're engaged in with drug companies,
03:46we cannot seek to negotiate the prices of some of those drugs that you just mentioned until
03:53they've been on the market for many, many years.
03:56Yes, you are.
03:58So we have taken that into account. Innovation, we take into account what they charge or what
04:03they say they invest in research and development in any price negotiation.
04:06All right, yes is what I needed to hear. Back in February, the National Association of Attorneys
04:11General sent a letter to congressional leaders on behalf of a bipartisan group of 39 attorneys
04:15generals, including Georgia's AG Chris Carr, urging action on pharmacy benefit manager practices.
04:22This letter outlines several PBM practices such as spread pricing, tying their own compensation
04:28to the list price of medicine that are increasing cost of millions of patients,
04:32employers, and community pharmacies, not only in my state but across the country.
04:38Since you've mentioned on record that HHS is currently enforcing the drug price transparency
04:44rule, I'm assuming that you also agree something needs to be done to protect patients and
04:49stakeholders from such practices?
04:52As I mentioned, PBMs, we would all like to do more.
04:54That would be a yes?
04:56We would all like to see you do more when it comes to PBMs.
04:59Okay, I have a few more questions. I'll submit those for the record.
05:03I'm out of time and I'll yield back. Thank you.
05:05Thank you, Mr. Allen. Ms. Jayapal, you're recognized.

Recommended